Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Market price (% of par)
-
105.81%
-
Total 13F principal
-
$707,502,041
-
Principal change
-
-$28,178,010
-
Total reported market value
-
$750,572,002
-
Number of holders
-
57
-
Value change
-
-$21,159,427
-
Number of buys
-
23
-
Number of sells
-
21
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q1 2025
As of 31 Mar 2025,
HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by
57 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$707,502,041
in principal (par value) of the bond.
The largest 10 bondholders included
Voya Investment Management LLC, Linden Advisors LP, Opti Capital Management, LP, LAZARD ASSET MANAGEMENT LLC, Calamos Advisors LLC, BlackRock, Inc., CAMDEN ASSET MANAGEMENT L P /CA, Wellesley Asset Management, BNP PARIBAS FINANCIAL MARKETS, and BANK OF AMERICA CORP /DE/.
This page lists
57
institutional bondholders reporting positions
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.